• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by InspireMD Inc.

    8/4/25 4:05:07 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001433607
    Saguaro Resources, Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    InspireMD, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    InspireMD, Inc.
    Street Address 1 Street Address 2
    6303 WATERFORD DISTRICT DRIVE SUITE 215
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    MIAMI FLORIDA 33126 (888) 776-6804

    3. Related Persons

    Last Name First Name Middle Name
    Slosman Marvin
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    President and Chief Executive Officer
    Last Name First Name Middle Name
    Lawless Mike
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer
    Last Name First Name Middle Name
    Tommasoli Andrea
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Operating Officer
    Last Name First Name Middle Name
    Gleason Shane
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Verta Patrick
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ligotti Pete
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Stuka Paul
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Berman Michael
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kester Thomas J.
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Roubin, M.D. Gary
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Arnold Kathryn
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cohen Raymond
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ward Scott R.
    Street Address 1 Street Address 2
    InspireMD, Inc. 6303 Waterford District Drive, Suite 215
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33126
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
    X Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-07-30    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    Shares of Common Stock & Warrants, including underlying common stock

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    BofA Securities, Inc. 000283942
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    One Bryant Park
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10036
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
    X All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $40,064,989 USD
    or    Indefinite
    Total Amount Sold $40,064,989 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    18

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $2,388,900 USD
    X Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    InspireMD, Inc. /s/ Marvin Slosman Marvin Slosman President and CEO 2025-08-04

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $NSPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    2/2/2026$6.00Buy
    Maxim Group
    More analyst ratings

    $NSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on InspireMD with a new price target

    Maxim Group initiated coverage of InspireMD with a rating of Buy and set a new price target of $6.00

    2/2/26 7:53:56 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stuka Paul bought $9,182 worth of shares (5,073 units at $1.81), increasing direct ownership by 1% to 391,628 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/11/25 4:05:09 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $9,436 worth of shares (5,073 units at $1.86), increasing direct ownership by 1% to 388,918 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/8/25 4:05:12 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $18,740 worth of shares (10,130 units at $1.85), increasing direct ownership by 3% to 383,845 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/5/25 4:05:02 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the "Inducement Grants") outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted u

    1/20/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

    The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company's C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Cardiology (JACC). The data demonstrate the safety and efficacy of carotid artery stenting (CAS) with the Company's MicroNet™ covered stent in patients with asymptomatic carotid stenosis. As shown at

    1/12/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

    MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated positive clinical outcomes for carotid artery stenting (CAS) for patients with asymptomatic carotid stenosis. CREST-2 data was shown at The Society of Vascular and Interventional Neurology (SVIN) Annual Meeting and the Vascular and Endovascular Issues Techniques and Horizons (VEITH) Symposium on November 21, 2025. In conjunction, the CREST-2 study was published in the New England Journal of Medicine. CREST-2 showed that, amo

    11/24/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Gleason Shane Thomas sold $99,331 worth of shares (61,194 units at $1.62), decreasing direct ownership by 5% to 1,139,177 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    2/2/26 5:01:41 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Ward Scott R. was granted 88,053 shares, increasing direct ownership by 147% to 147,846 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    1/16/26 6:12:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Tommasoli Andrea was granted 226,695 shares, increasing direct ownership by 31% to 954,389 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    1/16/26 6:11:38 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    SEC Filings

    View All

    InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    12/19/25 4:15:42 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by InspireMD Inc.

    S-8 - InspireMD, Inc. (0001433607) (Filer)

    11/18/25 4:15:40 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by InspireMD Inc.

    SCHEDULE 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/25 6:12:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

    MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. "We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company," said Marvin Slosman, Chief Executive Officer of InspireMD. "His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insight

    11/3/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    10/28/24 4:02:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Financials

    Live finance-specific insights

    View All

    InspireMD Reports Third Quarter 2025 Financial Results

    MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across leading hospitalsStrengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical OfficerAppointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD Marvin Slosma

    11/4/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Third Quarter 2025 Financial Results

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

    10/21/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Reports Second Quarter 2025 Financial Results

    --- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent systemCommenced commercial launch of the CGuard Prime carotid stent system in the U.S. MarketRaised $58 million in gross proceeds from an equity private placement and the exercise of existin

    8/5/25 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care